Table 2 Patient characteristics
Total N (%) or Median (range) | Hepatocarcinoma | Hepatic metastases | Cholangiocarcinoma | p* | |
|---|---|---|---|---|---|
Sex | |||||
Male | 78 (65%) | 32 (76.2%) | 42 (58.3%) | 4 (66.7%) | 0.14 |
Female | 42 (35%) | 10 (23.8%) | 30 (41.7%) | 2 (33.3%) | |
Age | 67 (23--85) | 69 (43--85) | 64 (23--83) | 70 (62--78) | 0.16 |
Weight (kg): | 78 (43--120) | 83 (47--120) | 74.5 (43--115) | 73 (68--85) | 0.07 |
BMI | 26.1 (14.2--43.3) | 29 (20.5--40.6) | 25.6 (14.2--43.3) | 27.1 (23.5--32) | 0.03 |
WHO | |||||
0 | 92 (77.3%) | 31 (73.8%) | 58 (81.7%) | 3 (50%) | |
1 | 23 (18.5%) | 11 (26.2%) | 9 (12.7%) | 2 (33.3%) | 0.08 |
2 | 4 (3.4%) | 0 | 3 (4.2%) | 1 (16.7%) | |
3 | 1 (0.8%) | 0 | 1 (1.4%) | 0 | |
Prior treatments | 114 (95%) | 19 (45.2%) | 66 (91.7%) | 3 (50%) | < 0.001 |
Radiofrequency | 11 (9.2%) | 2 (4.8%) | 9 (12.5%) | 0 | 0.38 |
Surgery | 31 (25.8%) | 4 (9.5%) | 24 (33.3%) | 3 (50%) | 0.003 |
Chemo--embo | 8 (6.7%) | 6 (14.3%) | 2 (2.8%) | 0 | 0.11 |
Radiotherapy | 2 (1.7%) | 1 (2.4%) | 1 (1.4%) | 0 | 0.87 |
Chemotherapy | 62 (51.7%) | 6 (14.3%) | 54 (75%) | 2 (33.3%) | < 0.001 |
Hepatic volume (cm 3 ) | 1548 (843–2940) | 1614 (908–2611) | 1499 (843–2940) | 1783 (1607–2018) | 0,19 |
Targets size (Sum in mm per patient) | 45 (8–159) | 40(17–145) | 45 (8–159) | 63 (36–112) | 0,24 |